HEALTHCARE UTILIZATION AND COSTS IN PULMONARY ARTERIAL HYPERTENSION (PAH) PATIENTS TREATED WITH ENDOTHELIN RECEPTOR ANTAGONISTS (ERAS) OR PHOSPHODIESTERASE TYPE 5 INHIBITORS (PDE5IS)

被引：0
|
作者：
Hill, J. [1 ]
Lickert, C. [2 ]
Cole, M. [2 ]
McGuiness, K. [1 ]
Wade, R. L. [1 ]
Drake, W. [2 ]
机构：
[1] QuintielsIMS, Plymouth Meeting, PA USA
[2] Actelion Pharmaceut Inc, San Francisco, CA USA
来源：
VALUE IN HEALTH | 2017年 / 20卷 / 05期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCV10
引用
下载
收藏
页码：A260 / A260
页数：1
相关论文
共 50 条
  • [1] MEDICATION ADHERENCE AND RISK OF HOSPITALIZATION IN PULMONARY ARTERIAL HYPERTENSION (PAH) PATIENTS TREATED WITH ENDOTHELIN RECEPTOR ANTAGONISTS (ERAS) OR PHOSPHODIESTERASE TYPE 5 INHIBITORS (PDE5IS)
    Hill, J. W.
    Lickert, C. B.
    Cole, M. R.
    Wade, R. L.
    Tsang, Y.
    Drake, W.
    VALUE IN HEALTH, 2017, 20 (09) : A620 - A620
  • [2] Medication adherence, hospitalization, and healthcare resource utilization and costs in patients with pulmonary arterial hypertension treated with endothelin receptor antagonists or phosphodiesterase type-5 inhibitors
    Frantz, Robert P.
    Hill, Jerrold W.
    Lickert, Cassandra A.
    Wade, Rolin L.
    Cole, Michele R.
    Tsang, Yuen
    Drake, William, III
    PULMONARY CIRCULATION, 2020, 10 (01)
  • [3] Oral Therapies for Pulmonary Arterial Hypertension Endothelin Receptor Antagonists and Phosphodiesterase-5 Inhibitors
    Channick, Richard
    Preston, Iona
    Klinger, James R.
    CLINICS IN CHEST MEDICINE, 2013, 34 (04) : 811 - +
  • [4] Survival of Japanese Patients with Pulmonary Arterial Hypertension after the Introduction of Endothelin Receptor Antagonists and/or Phosphodiesterase Type-5 Inhibitors
    Sakao, Seiichiro
    Tanabe, Nobuhiro
    Kasahara, Yasunori
    Tatsumi, Koichiro
    INTERNAL MEDICINE, 2012, 51 (19) : 2721 - 2726
  • [5] Simultaneous quantification of endothelin receptor antagonists and phosphodiesterase 5 inhibitors currently used in pulmonary arterial hypertension
    Enderle, Yeliz
    Witt, Lukas
    Wilkens, Heinrike
    Gruenig, Ekkehard
    Haefeli, Walter E.
    Burhenne, Juergen
    JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2017, 143 : 291 - 298
  • [6] Predictors of the response to combined therapy with phosphodiesterase-5 inhibitors and endothelin receptor antagonists in pulmonary arterial hypertension
    Garcia, A. R.
    Blanco, I.
    Lopez Meseguer, M.
    Domingo Morera, J. A.
    Martin Ontiyuelo, C.
    Tura Ceide, O.
    Otero Gonzalez, I.
    Escribano Subias, P.
    Albert Barbera, J.
    EUROPEAN RESPIRATORY JOURNAL, 2022, 60
  • [7] Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension
    David Montani
    Marie-Camille Chaumais
    Laurent Savale
    Delphine Natali
    Laura C. Price
    Xavier Jaïs
    Marc Humbert
    Gérald Simonneau
    Olivier Sitbon
    Advances in Therapy, 2009, 26 : 813 - 825
  • [8] Phosphodiesterase Type 5 Inhibitors in Pulmonary Arterial Hypertension
    Montani, David
    Chaumais, Marie-Camille
    Savale, Laurent
    Natali, Delphine
    Price, Laura C.
    Jais, Xavier
    Humbert, Marc
    Simonneau, Gerald
    Sitbon, Olivier
    ADVANCES IN THERAPY, 2009, 26 (09) : 813 - 825
  • [9] Efficacy and safety of endothelin receptor antagonists, phosphodiesterase type 5 Inhibitors, and prostaglandins in pediatric pulmonary arterial hypertension: A network meta-analysis
    Cao, Fen
    Wu, Kun
    Zhu, Yong-zhi
    Jiang, Jun-jun
    Zhang, Gui
    Liu, Jun
    Xiao, Ping
    Tian, Yang
    Zhang, Wei
    Zhang, Sheng
    Hou, Feng
    Bao, Zhong-wu
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2023, 9
  • [10] Phosphodiesterase type 5 inhibitors in the treatment of pulmonary arterial hypertension
    Kilickesmez, Kadriye
    Kucukoglu, M. Serdar
    ANATOLIAN JOURNAL OF CARDIOLOGY, 2010, 10 : 16 - 18
12345